Responses
Translational research/biomarkers
2022-RA-1198-ESGO Post hoc analysis of objective response rate by mismatch repair protein dimer loss/mutation status in patients with mismatch repair deficient endometrial cancer treated with dostarlimab
Compose a Response to This Article
Other responses
No responses have been published for this article.